More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions.

Leaders from major multinationals, including Apple Inc. (NASDAQ:AAPL) and Eli Lilly and Co. (NYSE:LLY), emphasized opportunities tied to China's consumer base following years of disruption from the COVID-19 pandemic, economic slowdown, and trade frictions.

The discussions reflected a cautious but clear pivot toward expansion, as Beijing continues to gradually ease restrictions on foreign businesses.

Eli Lilly Expands China Bet With Obesity Drug Focus

In March, Eli Lilly outlined an aggressive long-term strategy for China, announcing plans to invest $3 billion in the country over the next decade. The move comes as the company looks to scale its presence in a market that contributed less than 3% of its revenue last year.

David A. Ricks, the company's CEO, told CNBC that strong potential for its GLP-1 obesity treatment portfolio, particularly if reimbursement frameworks improve. He noted that broader insurance coverage could unlock meaningful demand.

China has already taken steps in that direction. Lilly's weight-loss drug Mounjaro was recently added to the state-run health insurance reimbursement list, marking a key milestone for market access.

Supreme Court Revives High-Stakes Actos Litigation

In a separate development, the U.S. Supreme Court allowed a multibillion-dollar lawsuit against Takeda Pharmaceutical Co. Ltd (NYSE:TAK) and Eli Lilly to proceed.

Bloomberg highlighted that the case alleges the companies marketed the diabetes drug Actos without adequately disclosing potential bladder cancer risks.

The court declined to review an appeal challenging the certification of a class action involving insurers and other third-party payers.

The plaintiffs argue they incurred higher costs due to incomplete risk disclosures tied to the drug.

Bloomberg reported industry groups, including the U.S. Chamber of Commerce and the Pharmaceutical Research and Manufacturers of America, backed the companies' appeal, warning that the ruling could broaden exposure to large-scale class actions.

Legal and Market Pressures Converge For Pharma

The plaintiffs maintain most class members were affected, citing a high probability of financial injury tied to Actos prescriptions. Meanwhile, the companies argue that identifying specific harm across millions of prescriptions remains impractical.

The case adds to ongoing legal scrutiny for pharmaceutical companies even as they pursue growth in international markets such as China, highlighting a dual-track environment of expansion opportunities and litigation risks.

LLY Stock Price Activity: Eli Lilly shares were 0.75% at $913.46 at the time of publication on Monday, according to Benzinga Pro data.

Image via Shutterstock